Protocol Ledger

NCT04002297 · Phase III · ACTIVE NOT RECRUITING

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Interventional Phase III clinical trial protocol NCT04002297 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-20 Enrollment: 510 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04002297
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)510 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04002297
Protocol FieldVerified Registry Value
NCT IdentifierNCT04002297
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment510 participants (ACTUAL)
Registered Start Date2019-08-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI